Reported July 16: Takeda Announces New Data From Two Phase 3 Studies Of Zasocitinib In Adults With Plaque Psoriasis; Secondary Endpoint Data Indicate Consistent And High Rates Of Skin Clearance

Loading news article.

Reported July 16: Takeda Announces New Data From Two Phase 3 Studies Of Zasocitinib In Adults With Plaque Psoriasis; Secondary Endpoint Data Indicate Consistent And High Rates Of Skin Clearance | WAPE

Reported July 16: Takeda Announces New Data From Two Phase 3 Studies Of Zasocitinib In Adults With Plaque Psoriasis; Secondary Endpoint Data Indicate Consistent And High Rates Of Skin Clearance

Article summary

Related companies

Comments —